Gilead's Cayston Picks Up Panel Endorsement, But Not Based On Data
• By The Pink Sheet
It was the orphan setting and urgent need for new therapies to treat the respiratory and pulmonary symptoms of cystic fibrosis that led FDA's Anti-Infective Drugs Advisory Committee to support approval of Gilead's Cayston (aztreonam lysine)
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
